key: cord-0715074-e9qxs9zy
authors: Cui, Dan; Wang, Yeming; Huang, Lixue; Gu, Xiaoying; Huang, Zhisheng; Mu, Shengrui; Wang, Chen; Cao, Bin
title: Rheumatic symptoms following COVID-19: a chronic post COVID-19 condition
date: 2022-04-04
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac170
sha: 0f98f8619f434f185162fa35948e7ff474a03cdb
doc_id: 715074
cord_uid: e9qxs9zy

BACKGROUND: Detailed characteristics of rheumatic symptoms of COVID-19 were still unknown. We aim to investigate the proportions, characteristics, and risk factors of this condition. METHODS: In this prospective, longitudinal cohort study, discharged patients with COVID-19 were face-to-face interviewed at 12 months after symptom onset. Rheumatic symptoms following COVID-19 included newly occurring joint pain, and (/or) joint swelling after COVID-19. The risk factors of developing rheumatic symptoms were identified by multivariable logistic regressions. RESULTS: In total, 1296 of 2469 discharged patients with COVID-19 were enrolled in this study. Among them, 160 (12.3% [95% CI 10.6, 14.3]) suffered from rheumatic symptoms following COVID-19 at 12-month follow-up. The most frequently involved joints were the knee joints (38%), followed by hand (25%) and shoulder (19%). Rheumatic symptoms were independent of the severity of illness and corticosteroid treatment during acute phase, while elderly (OR 1.22, 95%CI 1.06, 1.40) and women (OR 1.58, 95%CI 1.12, 2.23) were identified as the risk factors for this condition. CONCLUSIONS: Our investigation showed a considerable proportion of rheumatic symptoms following COVID-19 in discharged patients, which highlights the need for continuing attention. Notably, rheumatic symptoms following COVID-19 were independent of the severity of illness and corticosteroid treatment during acute phase.

A c c e p t e d M a n u s c r i p t 3 

We searched PubMed between Jan 3 and Oct 1, 2021, for studies with the terms "(COVID-19 OR 2019-ncov OR SARS-CoV-2) AND (survivor* OR recover* OR persistent OR follow up OR discharge* OR long term OR sequelae) AND (joint* OR arthralgia OR arthritis OR musculoskeletal)" without language restriction. Rheumatic symptoms, together with a collection of long-term manifestations of COVID-19, were identified by various follow-up studies worldwide. We found case series reporting musculoskeletal manifestation and rheumatic disorders during acute phase COVID-19. However, we are not aware of any data regarding the detailed characteristics or associated risk factors of rheumatic symptoms following COVID-19.

To our knowledge, we provide the first detailed description of rheumatic symptoms at 12 months after COVID-19 symptom onset and estimate the risk factors. We found 12.3% of discharged patients developed rheumatic symptoms following COVID-19. The most involved joint was knee, followed by hand and shoulder, with the pain intensity between mild to moderate. For the quality of life, five dimensions were impaired in patients with rheumatic symptoms following COVID-19 compared with those without, including mobility, self-care, usual activity capabilities, pain/discomfort, and anxiety/depression. Rheumatic symptoms following COVID-19 were independent of the severity of illness and corticosteroid treatment during acute phase, while older age and women were identified as the risk factors for this condition.

A c c e p t e d M a n u s c r i p t 4 

In this study, a considerable proportion of COVID-19 patients are suffering from rheumatic symptoms at 12 months after symptom onset, which highlights the need for continuing attention. Our data may provide reference and evidence for future clinical research and related pathological mechanism hypothesis of COVID- 19. A c c e p t e d M a n u s c r i p t 5 Abstract:

Detailed characteristics of rheumatic symptoms of COVID-19 were still unknown. We aim to investigate the proportions, characteristics, and risk factors of this condition.

In this prospective, longitudinal cohort study, discharged patients with COVID-19 were faceto-face interviewed at 12 months after symptom onset. Rheumatic symptoms following COVID-19 included newly occurring joint pain, and (/or) joint swelling after COVID-19. The risk factors of developing rheumatic symptoms were identified by multivariable logistic regressions.

In total, 1296 of 2469 discharged patients with COVID-19 were enrolled in this study.

Among them, 160 (12.3% [95% CI 10.6, 14.3]) suffered from rheumatic symptoms following COVID-19 at 12-month follow-up. The most frequently involved joints were the knee joints (38%), followed by hand (25%) and shoulder (19%). Rheumatic symptoms were independent of the severity of illness and corticosteroid treatment during acute phase, while elderly (OR 1.22, 95%CI 1.06, 1.40) and women (OR 1.58, 95%CI 1.12, 2.23) were identified as the risk factors for this condition.

Our investigation showed a considerable proportion of rheumatic symptoms following COVID-19 in discharged patients, which highlights the need for continuing attention. M a n u s c r i p t 7

As of 11 Oct 2021, COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been diagnosed in more than 462 million people worldwide, causing the death of more than 6.0 million. 1 A collection of long-term manifestations of COVID-19, including fatigue, shortness of breath, loss of taste or smell, etc. were identified by various follow-up studies from different countries, which has been termed "post-acute COVID-19 syndrome (PCS)". 2 Rheumatic symptom, as a long-term manifestation of COVID-19, has been frequently come up in various published follow-up studies. [3] [4] [5] [6] [7] [8] [9] [10] [11] It was known that viral infection, such as parvovirus B19, hepatitis B and C, human immunodeficiency virus (HIV), and the alphaviruses, was recognized as an important cause of virally mediated arthritis, with a wide spectrum of rheumatic symptoms, ranging from arthralgia to chronic arthritis. 12 Rheumatic symptoms after other coronavirus infection, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), was also reported with an incidence of 10% and 32% respectively. It is worth noting that, the incidence may be underestimated under the scenarios of high doses of glucocorticoids (cumulative doses during hospitalization of >1g). [13] [14] [15] Although the condition of rheumatic symptoms following COVID-19 has been noticed in some studies, the details of proportion and clinical characteristics have not yet been well described. And the risk factors of the presence of rheumatic symptoms following COVID-19 were unknown. Thus, the objective of this study was to investigate the proportion, describe the characteristics, and identify the potential factors of rheumatic symptoms following COVID-19 among discharged patients.

A c c e p t e d M a n u s c r i p t 8 Methods:

This prospective, single-center cohort study was conducted at the designated hospital at 12 months after COVID-19 symptom onset. All laboratory confirmed patients admitted to the designated hospital met the diagnostic criteria for COVID-19. 16 A total of 2469 patients were discharged between Jan 7, and May 29, 2020 as previously reported. 9 All the 2469 patients were eligible for inclusion. We contacted the patients in the order of the symptom onset date documented in their medical record via telephone. Patients were excluded if they met the following criterion: (1) those who died before the follow-up visit; (2) those who living in nursing or welfare home; (3) those who had a history of dementia or psychotic disease; (4) those who had a history of rheumatic disease (including osteoarticular disease), or immobile before or after discharge. Eligible patients were invited to participate the face-to-face interview at the outpatient clinic of the hospital, and 905 patients were lost to follow-up. A total of 1296 patients who completed the interview and symptom questionnaire at hospital from Dec 16, 2020 to Feb 7, 2021 were enrolled in this study ( Figure 1 ). We evaluated the proportions of self-reported rheumatic symptoms following COVID-19 through symptom questionnaire, and obtained detailed characteristics.

The rheumatic symptoms following COVID-19 were defined as self-reported newly occurring joint symptoms after COVID-19, including joint pain, and (or) joint swelling. We list 10 joint groups (including hand, foot, wrist, ankle, jaw, elbow, shoulder, neck, hip, and knee) for patients to choose the location of the symptomatic joint site (any other if yes, specify additionally). The hand joint group included the metacarpophalangeal joints (MCP), the distal interphalangeal joints (DIP), the proximal interphalangeal joints (PIP), and the interphalangeal joint of the thumb (IP). Symptom localizing to the chest, abdomen, or back A c c e p t e d M a n u s c r i p t 9 was not considered for further analysis. In addition, we conducted the EQ-5D-5L questionnaire and 6-min walking test to evaluate the QoL of patients.

As control, 3383 community-dwelling individuals without SARS-CoV-2 infection were recruited. Methods, inclusion, and exclusion criteria of control have been described previously 17 . For every SARS-CoV-2 survivor, we randomly sampled up to one individual with control, without replacement, matching age, sex, and comorbidities including cardiovascular disease, chronic respiratory disease, chronic kidney disease, hypertension, and diabetes ( Figure 1 , dotted line marked).

The study was approved by the Research Ethics Commission of the designated hospital which enrolled the participants (KY-2020-78.01, KY-2020-78.03). Written informed consent was obtained from all patients and controls.

Data collection consisted of three parts, including demographic data, acute phase data, and follow-up data.

The patients' demographic data were retrieved from electronic medical records, which including age, sex, education, and cigarette smoking.

We collected clinical data during hospital stay for acute phase, such as symptoms, selfreported comorbidities, and medication history, disease severity, and treatment record from REDCap electronic database. The severity of disease was characterized by the highest sevencategory scale during the hospital stay (termed the seven-category) 18 Follow-up data were collected via face-to-face interviews at the outpatient clinic of the hospital. Physicians were arranged for the patients to complete a structured symptom questionnaire to ask if the patients had any obvious discomfort after discharge. Patients with self-reported newly occurring and persistent rheumatic symptoms after COVID-19 were further asked for more details about their joint complaints. We provided 10 joint groups aforementioned for patients to choose from. For each pain joint location, an 11-point NPS ranging from 0 to 10 (0 no pain, 10 intolerable pain), was applied to evaluate the intensity. 19 And the score was categorized as mild (score 1-3), moderate (score 4-6), and severe (score 7-10). Joint swelling was recorded at the same time.

Data of community-dwelling non-COVID-19 individuals were collected via face-to-face interviews at their community center by medical staff from the same hospital. Demographic characteristics, personal medical history, and lifestyle information were collected via standard questionnaires. Then, non-COVID-19 individuals underwent physical examination, and prevalent symptoms and EQ-5D-5L questionnaires.

Descriptive analyses of the continuous variables were expressed as median (IQR), and categorical variables were expressed as n (%). Demographic characteristics and clinical data A c c e p t e d M a n u s c r i p t 11 for acute phase between patients with or without rheumatic symptoms following COVID-19 were shown. For the comparison of health-related quality of life and exercise capacity between the two groups, we used the Mann-Whitney U test, χ2 test, or Fisher's exact test where appropriate. For comparison of symptoms and health-related quality of life between COVID-19 patients and controls was done with Mann-Whitney U test, χ2 test, or Fisher's exact test where appropriate, as well.

The rheumatic symptoms following COVID-19 was included as the dependent variable in a univariable logistic regression model (crude association), and were then corrected for several covariables. Variables included in the multivariable adjusted logistic regression models are as follows: age, gender, comorbidity including hypertension, diabetes, and cardiovascular disease, disease severity, medical treatment including corticosteroids, antivirals, thymosin, and intravenous immunoglobulin, length of hospital stay and admission of ICU. For association of gender, corticosteroids, antivirals, thymosin, and intravenous immunoglobulin, length of hospital stay and admission of ICU with rheumatic symptoms, these variables were included in the models together with age, disease severity and comorbidity including hypertension, diabetes, and cardiovascular disease were also adjusted.

For association of disease severity and rheumatic symptoms, the aforementioned variables were all adjusted in the model, except for length of hospital stay and admission of ICU.

Disease severity was not included in the model when exploring the association of comorbidity with rheumatic symptoms. In the model for association of age and rheumatic symptoms, only age and gender were adjusted.

All tests were 2-sided, and a P-value less than 0.05 was considered statistically significant. Data were analyzed with the use of SAS, version 9.4. Statistical graphs were drawn with GraphPad Prism8 and Adobe Illustrator 2020. (Table 1 ). The most common comorbidity was hypertension (28%), followed by diabetes (12%) and cardiovascular disease (9%).

In total, 12.3% (95% CI 10.6, 14.3) of COVID-19 patients (160/1296) complained they were suffering from at least one newly occurring or persistent rheumatic symptom after COVID-19. Of 160 patients, the median age was 60.0 years (IQR 53.0-65.0 years), 90 (56%) of them were women, 40 (28%) had college or higher education. Hypertension (29%), cardiovascular disease (13%), and diabetes (12%) were the most common comorbidities.

Table S1 showed the relative risk of variables to presence of rheumatic symptoms following COVID-19. Older age, women, and prolonged hospital stay increased the risk of rheumatic symptoms. Whereas, rheumatic symptoms following COVID-19 were independent of the severity of illness and corticosteroid treatment during acute phase (Table S2) .

For exploring the risk factors associated with rheumatic symptoms, available data from 1296 patients (1136 without and 160 with rheumatic symptoms), and 4 logistic regression A c c e p t e d M a n u s c r i p t 13 models were performed. After multivariable adjustment, patients with older age had a higher risk of rheumatic symptoms (OR 1.22, 95%CI 1.06, 1.40, per 10-year age increase).

Compared with men, women had an OR of 1.58 (95% CI 1.12, 2.23) for presenting rheumatic symptoms following COVID-19 (Table 2) .

Of 160 patients reported rheumatic symptoms following COVID-19 at 12-month follow-up, the proportions in men and women were 10% (70/687) and 15% (90/609) respectively. The age distributions of rheumatic symptoms following COVID-19 were shown in Figure 3B showed the frequencies of joint sites among patients with rheumatic symptoms following COVID-19. The most common joint was the knee joint (38%), followed by hand (25%, including MCP, PIP, or DIP, etc.) and shoulder (19%). For all rheumatic symptoms, joint pain only (86%) was mainly represented, joint pain concomitant joint swelling (8%) and joint swelling only (5%) were relatively rare. The intensity of joint pain was detailed in Figure 3A , and be graded as mild to moderate. Rheumatic symptoms reported in one joint site (86%) was the most common type, followed by in 2-4 joint sites (12%), and in 5 or more joint sites (3%; Figure 3C ). There was no significant improvement in the proportions of COVID-19 patients with joint pain between 6-month and 12-month follow-up visits (P=0.092, Table S3 ). 

EQ-5D-5L questionnaire was used to evaluate the QoL. At 12-month follow-up, all dimensions of health-related QoL were impaired in patients with rheumatic symptoms following COVID-19 compared with those without, including mobility, self-care, usual activity capabilities, pain/discomfort, and anxiety/depression (all P<0.05; Table S4 ). Patients with rheumatic symptoms had less distance walked in 6 min (480.0m vs 497.0m, P=0.018) compared to those without. While there were no significant differences in the proportion of lower limit of the normal range (LLN) between two COVID-19 patient groups (Table S4) .

To compare the prevalence of rheumatic symptoms between COVID-19 and non-COVID-19 adults, 3383 community-dwelling individuals without SARS-CoV-2 infection were recruited.

individuals. The differences of age, sex, and comorbidities between COVID-19 and non-COVID-19 cohorts were eliminated after propensity score match (Table S5) . 301 of 1181 (25%) COVID-19 patients had at least one rheumatic symptoms, which was significantly higher than for controls (89/1181 [8%], P<0.0001). Pain joint sites and swelling joint sites were detailed in Table 3 . 

Arthralgia/arthritis has been increasingly reported in the setting of COVID-19, which has aroused wide attention of the clinician 20,21 , but several important issues remain unsettled. In this prospective cohort study, 12.3% of discharged patients developed rheumatic symptoms following COVID-19 at 12-month follow-up. Of the 160 patients presenting rheumatic symptoms, the most involved joint was the knee, followed by hand and shoulder. Joint pain was the most common presentation, with the pain intensity graded between mild to moderate.

Notably, rheumatic symptoms following COVID-19 were independent of the severity of illness and corticosteroid treatment during acute phase.

In comparison of community-dwelling controls, COVID-19 patients reported significantly more rheumatic symptoms, indicating that COVID-19 patients did not recover to general status until 12 months after symptom onset. Previous studies suggest that viral infection is one of the well-recognized causes of arthralgia. Many kinds of viruses, including coronaviruses, can cause varying degrees of joint disease. 12 A large retrospective study from south Korea showed that ambient respiratory viral infections by coronavirus, parainfluenza virus, and metapneumovirus were associated with an increased number of incident rheumatoid arthritis (RA). 22 On the basis of the published follow-up studies of COVID-19 so far, the proportion of self-reported rheumatic symptoms following COVID-19 ranged from 4.5% to 27.3% [3] [4] [5] [6] [7] [8] [9] . The differences in illness severity of the study populations, the differences in trial designs, and even the differences in virus strains might be the explanations for the varied proportions. The prevalence of joint symptoms caused by other viral infections continues to evolve. Rubella, for instance, becomes less common due to vaccination, while some alphaviruses have become more widespread 12 . Despite these viral infectious diseases in humans are usually self-A c c e p t e d M a n u s c r i p t 16 limiting, from the limited experience, rheumatic symptoms caused by these diseases usually lasts weeks to months and can be protracted 23 .

The possible causes of rheumatic symptoms following COVID-19 may be musculoskeletal disorders before COVID-19, gout, or rheumatic symptoms specific following the infection with SARS-CoV-2, which need to be further demonstrated by orthopedist or rheumatologist through complete examinations. 24 So far, the specific mechanism of rheumatic symptoms following COVID-19 remains unclear, but several hypotheses have been proposed. Firstly, excessive or uncontrolled cytokine responses in COVID-19 patients, including interleukin 17 (IL-17) and tumor necrosis factor (TNF), as important therapeutic targets in spondyloarthritis and psoriatic arthritis, also play an important role in the progress of COVID-19. 15 Several studies showed that the elevated level of IL-4, IL-9, and IL-13 in COVID-19 patients also played differently in the joints. 15, [25] [26] [27] Additionally, some antirheumatic drugs also appear to have potential efficacy in COVID-19, such as hydroxychloroquine, colchicine, baricitinib, and tocilizumab. 28 increased risk of severe COVID-19, on the contrary, more women were experiencing long COVID. Notably, we found that rheumatic symptoms following COVID-19 were not associated with the severity of illness and corticosteroid treatment during acute phase. A cross-sectional study from Anaya et al. corroborated this finding. 10 When assessing the QoL in patients with rheumatic symptoms following COVID-19, all five aspects of EQ-5D-5L questionnaire were mentioned impaired, reflecting the physical and mental impact of this condition. A prospective longitudinal study of CHIKV-infected French military policemen showed that individuals presented with rheumatic morbidity and impaired QoL persisted 6 years later. 34 In addition, SARS-CoV-1 can also directly or indirectly affect multiple organ systems, including the musculoskeletal system. Incapacitating arthralgia, muscle dysfunction, osteoporosis, and osteonecrosis are common sequelae of SARS-CoV-1, causing a serious decline of the QoL and even disability. 35 In this study, we found that of all pain joints, the intensity was graded mild to moderate. Severe impairment of mobility, selfcare, and usual activity capabilities were also rarely reported.

This study has several limitations. Firstly, this is a single-center study in a designated hospital for COVID-19 and specific to the virus strain that caused the Wuhan pandemic.

Secondly, due to lack of mechanism exploration, the observed rheumatic symptoms following COVID-19 cannot be directly attributed to COVID-19. Thirdly, lack of more detailed investigation of symptoms, such as whether joint involvement is symmetrical, and further examination methods, such as joint imaging and serologic markers, etc. In the future, 

We found a considerable proportion of rheumatic symptoms following COVID-19 in discharged patients at 12-month after symptom onset, which highlights the need for continuing attention. Notably, rheumatic symptoms following COVID-19 were independent of the severity of illness and corticosteroid treatment during acute phase. Our data may provide reference and evidence for future clinical research and related pathological mechanism hypothesis of COVID-19. For association of gender, corticosteroids, antivirals, thymosin, and intravenous immunoglobulin, length of hospital stay and admission of ICU with rheumatic symptoms, these variables were included in the models together with age, disease severity and comorbidity including hypertension, diabetes, and cardiovascular disease were also adjusted. For association of disease severity and rheumatic symptoms, the aforementioned variables were all adjusted in the model, except for length of hospital stay and admission of ICU. Disease severity was not included in the model when exploring the association of comorbidity with rheumatic symptoms. In the model for association of age and

Post-acute COVID-19 syndrome

Persistent Symptoms in Patients After Acute COVID-19

Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clinical microbiology and infection : the official publication of the

Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort

Incidence and risk factors: A Mediterranean cohort study

Long COVID in the Faroe Islands -a longitudinal study among non-hospitalized patients

Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Post-COVID syndrome. A case series and comprehensive review

Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic

Viral arthritis

Clinical infectious diseases : an official publication of the Infectious Diseases Society of

Middle East respiratory syndrome

COVID-19 revisiting inflammatory pathways of arthritis

Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale

Viral arthralgia a new manifestation of COVID-19 infection? A cohort study of COVID-19-associated musculoskeletal symptoms

A c c e p t e d M a n u s c r i p t 32 Figure 3